LSO Knowledge & Networking Forum – Friday, June 21st

Registration

 To register Click here. 

Topic & Guest Speakers

Member Marathon

  • Tom Reeves, Interface Biologics  

INTERFACE BIOLOGICS, INC. (IBI) is a privately held early commercial stage company that develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices. Their primary technology focus areas are anti-thrombogenic additives that reduce thrombosis and programmable combination drug delivery devices. The company was founded in 2001 based on the work of Dr. Paul Santerre at the University of Toronto.

  • Pam Chappell, Business Improvement Group  

Established in 2001, Business Improvement Group Inc. (BIG) is one of the largest, full-service Scientific Research and Experimental Development (SR&ED) consulting firms in Canada. With over 10,000 successful projects approved by Canada Revenue Agency (CRA), a success rate of over 98%, and a flexible, competitive pricing strategy, BIG is a recognized industry leader, providing reliable and accurate SR&ED claim preparation and support services to organizations of all sizes – from independent owner-operated businesses to multinational firms with thousands of employees – across a wide range of industries.

  • Thomas Wellner, CML HealthCare  

For over 40 years, CML HealthCare has been an essential part of Canadian diagnostic medicine. As the leading medical diagnostics provider in Canada, they are dedicated to helping physicians deliver the highest quality care to their patients. Today they operate more than 200 lab and diagnostic imaging sites across Canada and through those centres, they process over 40 million tests every year.

  • Jan Oudenes, Alphora Research

Alphora Research Inc. is a Mississauga-based Contract Research Organization (CRO) that provides process chemistry development and GMP scale-up manufacturing services to Pharmaceutical and Biotech companies for small molecule Active Pharmaceutical Ingredients (API’s).   Alphora’s core focus is at the early stage of API Technology Development, devising chemical processes and preparing materials for pre-clinical and clinical studies (non-GMP and cGMP).
Alphora is FDA inspected and approved, with facilities that total 45,000 sq. ft. and include cGMP Kilo Laboratories, cGMP Pilot Plant operations, organic and analytical laboratories, QC/QA, and a separate high potency/cytotoxic containment facility.
Founded in 2003 by Dr. Jan Oudenes, Alphora has an experienced management team with over 150 years of combined experience, plus a technical team with considerable talent and success in developing and implementing API technologies for hundreds of pre-clinical and clinical compounds.

  • Alina Ma and Quentin Wong, Students, University of Toronto Schools (winner Commercialization Award at the GTA Sanofi BioGENEius)

After being inspired by an article about Pestalotiopsis microspora degrading plastic, we decided to investigate a different fungus, Aspergillus flavus and its active enzyme responsible for polyester polyurethane degradation – likely an esterase.  We are looking to reverse-engineer the DNA from the protein capable of degrading the PUR and express it in a yeast, Pichia pastoris.

Where

Fasken Martineau DuMoulin LLP,
333 Bay Street, Suite 2400, Toronto, Ontario

7:30 am – Registration / Breakfast
8:00 am ‑ 9:30 am – Presentations

9:30 – 10:00 am – Networking

Share: